[Therapy and prevention of esophageal varices hemorrhage: current status].
Acute bleeding from esophageal varices is a medical emergency. It requires a structured therapeutic strategy adapted to local resources. The primary goal is to stop bleeding, preferably by endoscopic sclerotherapy or ligation. If endoscopic intervention is not possible as a first-line treatment, balloon tamponade or vasoactive drugs (terlipressin or octreotid) are therapeutic options to be followed as soon as possible by sclerotherapy or ligation. After successful hemostasis, the next goal is to prevent rebleeding. This is achieved primarily by eradicating sclerotherapy or ligation. In special situations, long-term therapy with a non-cardioselective beta receptor blocker is an alternative. The combined approach using sclerotherapy or ligation plus beta receptor blocker offers no significant advantage. Primary prophylaxis of bleeding from esophageal varices by long-term beta receptor blocker therapy is advised in patients with medium-sized or large varices. Apart from strategies aimed at the therapy or prophylaxis of bleeding from esophageal varices, measures to prevent or treat chronic liver diseases should be implemented in order to reduce the development of liver cirrhosis as the leading cause of esophageal varices.
Lammer
F
F
Departement für Innere Medizin, Universitätsspital Zürich.
Meyenberger
C
C
Blum
H E
HE
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D021721:Balloon Occlusion; D002404:Catheterization; D003131:Combined Modality Therapy; D004621:Embolization, Therapeutic; D004932:Esophageal and Gastric Varices / Q000150:complications* / Q000628:therapy; D004945:Esophagoscopy; D006471:Gastrointestinal Hemorrhage / Q000209:etiology / Q000517:prevention & control*; D006489:Hemostatic Techniques; D006801:Humans; D008026:Ligation; D012008:Recurrence; D015911:Sclerotherapy
D000319:Adrenergic beta-Antagonists
Therapie und Prophylaxe der Osophagusvarizenblutung: aktueller Stand.